

# Improved ' Cellion NADH ' – A Nutritional Supplement for Healthy Individuals Desiring More Natural Energy

**A Clinical Trial Reports Proven Energy Enhancement Using Strict FDA Testing Guidelines to Alleviate Symptoms of Chronic Fatigue Syndrome**

**WASHINGTON, DC, (February 23, 1999)** - - Formerly Menuco Corporation announced today that NADH<sup>®</sup>, a natural energy-enhancing nutritional supplement, tested by researchers at Georgetown University Medical Center, has achieved significant improvement in relieving the symptoms of people suffering from Chronic Fatigue Syndrome (CFS). CFS is a debilitating disorder caused by unexplainable tiredness or lack of energy, and has no known cure. According to the Centers for Disease Control, over 14 million people in the U.S. experience chronic fatigue symptoms. The Georgetown clinical trials focused on people diagnosed with CFS; however, NADH is also a nutritional supplement for healthy individuals who desire additional energy.

' NADH ' is one of the first nutritional supplements to be tested using strict FDA guidelines to determine its safety and effectiveness. Georgetown doctors found that 31% of the patients who took NADH achieved significant improvement in the relief of their symptoms. In a follow-up study, 72% of the patients achieved positive results over a longer period of time. The double-blind, placebo-controlled human clinical trial results have recently been published in a prominent medical peer-reviewed journal called "*Annals of Allergy, Asthma and Immunology*." The findings of these clinical trials are being presented at the February 23, 1999 press conference at Georgetown University Medical Center.

"Eighty percent of Americans state that fatigue is their number one health complaint. We demonstrate through sound scientific studies, not marketing hype, that NADH is both safe and effective in providing energy enhancement to alleviate the symptoms of CFS, a debilitating disorder which affects half a million Americans," said Matt Fitzsimmons, president, Menuco Corporation. "Dr. Bellanti and his research colleagues at Georgetown University Medical Center have successfully demonstrated NADH's effectiveness in increasing energy," says Fitzsimmons.

NADH is the brand name for stabilized, absorbable NADH (nicotinamide adenine dinucleotide plus high-energy hydrogen). It is the only patented, stabilized, absorbable, oral form of NADH currently on the market. For years, research scientists have known that NADH a natural coenzyme plays an important role in the body's cellular energy producing function. NADH occurs naturally in the muscle tissue of fish, poultry and cattle – key food sources in the human diet. However, the human body absorbs miniscule amounts of NADH ingested from food sources. Also it is known that the more NADH a cell has, the more energy it can produce; therefore, the more energy a person has.

In 1996, Co-Enzyme 1 received an Investigative New Drug (IND) acceptance from the FDA allowing NADH to begin a human double-blind, placebo-controlled, crossover study following strict pharmaceutical and drug testing guidelines. The protocol was recognized by the FDA and conducted at the prestigious Georgetown University Medical

Center in Washington, DC. (The IND number is 49,635 and the original working name of the product was Birmadil.)

Georgetown researchers are planning a large scale Chronic Fatigue Syndrome study using NADH to further explore its effectiveness for CFS. Also, Georgetown researchers are conducting an FDA approved clinical trial testing NADH to prevent the mental deterioration, memory lapses, and concentration difficulties associated with Alzheimer's disease. This study is being conducted under the direction of the department of neurology at Georgetown University Medical Center. NADH has shown promise in Europe when used for patients with Alzheimer's and Parkinson's diseases.

Birkmayer Laboratories in Vienna, Austria and Menuco Corporation sponsored the CFS study using NADH. Georg Birkmayer, MD, Ph.D., world-renowned biochemical researcher and director of the Birkmayer Institute for Parkinson Therapy, developed the first stabilized, absorbable oral NADH supplement, a result of a decade of research. He is also the first to use NADH therapeutically to stimulate the body to produce naturally the key brain chemicals responsible for energy production and muscle coordination

# # #

Notes: NADH is a dietary nutritional supplement, not a drug; however, NADH is believed to be one of the first nutritional supplements to follow strict FDA drug and pharmaceutical testing protocol in clinical trials at Georgetown University Medical Center.